公开(公告)号：US20230027148A1

公开(公告)日：2023-01-26

申请号：US17860873

申请日：2022-07-08

申请人： E.P.O.S. IASIS Research and Development Limited

发明人： Andreani Odysseos ,  Andreas Evdokiou ,  Anstasios Keramidas

IPC分类号： A61K47/54 ,  A61P35/00 ,  C07F9/40

摘要： The present invention provides compounds suitable for use in the treatment of conditions where it is beneficial to halt bone loss and kill cancer cells, particularly in metastases to and primary tumors in the bone and surrounding tissues. Consequently the present invention provides compounds comprising a bisphosphonate moiety linked to a phytochemical, pharmaceutical compositions thereof and methods of treatment of bone diseases and/or proliferative disorders.

公开(公告)号：US20220387458A1

公开(公告)日：2022-12-08

申请号：US17879285

申请日：2022-08-02

申请人： Applaud Medical, Inc.

发明人： Daniel J. Laser ,  Alice Luong ,  Robert G. Miotke

IPC分类号： A61K31/685 ,  A61K47/26 ,  A61K47/32 ,  A61P13/04 ,  A61K47/06 ,  A61K41/00 ,  A61K9/16 ,  A61K47/69 ,  A61K47/60 ,  A61K47/54 ,  A61K9/50 ,  A61K9/00 ,  A61K31/663 ,  C07F9/38 ,  C07F9/40

摘要： The present disclosure provides phospholipid-containing compounds, pharmaceutical compositions and microspheres that exhibit high affinity for mineralized metals. The present disclosure also provides strategies for using said compounds, compositions and microspheres in the treatment of nephrolithiasis or kidney stone disease, and methods of manufacturing and preparing said compounds and compositions.

公开(公告)号：US20220340550A1

公开(公告)日：2022-10-27

申请号：US17608881

申请日：2020-10-07

申请人： LT MATERIALS CO., LTD.

发明人： Seung-Gyu YANG ,  Su-Yeon KIM ,  Geon-Yu PARK ,  Young-Seok NO ,  Dong-Jun KIM

IPC分类号： C07D405/14 ,  C07F9/40 ,  C07D409/14 ,  C07F7/08 ,  C07D405/04 ,  C07D487/04 ,  C07D495/04 ,  C07D491/048 ,  C07D209/82 ,  H01L51/00 ,  H01L51/50 ,  H01L51/56

摘要： The present specification relates to an organic light emitting device, a method for manufacturing the same, and a composition for an organic material layer.

公开(公告)号：US20220298187A1

公开(公告)日：2022-09-22

申请号：US17636331

申请日：2020-10-19

申请人： Hepagene Therapeutics (HK) Limited

发明人： Shanghai Yu ,  Ben Li

IPC分类号： C07F9/6574 ,  C07F9/38 ,  C07F9/40 ,  C07F9/44

摘要： A chemical compound shown in formula (I) below and an isomer thereof or a pharmaceutically acceptable salt thereof. The compound improves THR-β agonistic activity while also improving selectivity for THR-α, thereby improving pharmaceutical quality.

公开(公告)号：US11345690B2

公开(公告)日：2022-05-31

申请号：US16299916

申请日：2019-03-12

申请人： Cayman Chemical Company, Inc.

发明人： Stephen Douglas Barrett ,  Joseph Michael Colombo ,  Bradlee David Germain ,  Andriy Kornilov ,  James Bernard Kramer ,  Adam Uzieblo

IPC分类号： C07D409/06 ,  C07D333/38 ,  C07D207/273 ,  C07D498/04 ,  C07F9/40

摘要： The present invention relates to processes and intermediates for preparing compounds of formula (IA), wherein R1, R4, R5, R6, and L1 are as defined herein. Compounds of formula (IA) have been found useful as EP4 receptor agonists useful in the treatment of glaucoma, osteoporosis, neuropathic pain, and related disorders.

公开(公告)号：US11174277B2

公开(公告)日：2021-11-16

申请号：US16736958

申请日：2020-01-08

申请人： Alliance for Sustainable Energy, LLC ,  Board of Trustees of Northern Illinois University

发明人： Kai Zhu ,  Tao Xu

IPC分类号： C07F9/40 ,  C07F9/38 ,  H01L31/042 ,  C08L71/02 ,  H02S40/38

摘要： The present disclosure relates to a composition that includes a sequestering material capable of binding a target material, where the sequestering material includes a first component that includes at least one of a functional group, a molecule, an oligomer, or a polymer, and the target material includes at least one of an element, a chemical, and/or a compound. In some embodiments of the present disclosure, the element may include at least one element from at least one of Rows 4, 5, 6, and 7 of the Periodic Table and/or an inner transition metal.

公开(公告)号：US20210319957A1

公开(公告)日：2021-10-14

申请号：US17258399

申请日：2019-08-01

申请人： TOKYO CHEMICAL INDUSTRY CO., LTD.

发明人： Hidetaka NISHIMURA ,  Iku OKADA ,  Taro TANABE ,  Atsushi WAKAMIYA

IPC分类号： H01G9/20 ,  C07C217/92 ,  C07D209/86 ,  C07C211/54 ,  H01L51/42 ,  H01L51/00 ,  C07C223/06 ,  C07C323/36 ,  C07C25/28 ,  C07D333/26 ,  C07D333/22 ,  C07D495/04 ,  C07D519/00 ,  C07C25/18 ,  C07F9/40

摘要： Provided are: a composition for forming a hole transporting layer for perovskite solar cells, which is inexpensive and does not need to be used together with a dopant; and a compound which can be contained in a composition for forming a hole transporting layer. A compound represented by general formula (I) (wherein Ar represents an aryl group; A represents a structure represented by formula (II); Z's independently represent a hydrogen atom, a structure represented by general formula (III), or a structure represented by formula (IV), and maybe the same as or different from each other, wherein a case where each of Z's is a hydrogen atom is excluded; Y's independently represents at least one member selected from the group mentioned below; R1 and R2 independently represents a hydrogen atom, an alkyl group or an alkoxy group, or R1 and R2 may together form a ring having one or two oxygen atoms; ×'s independently represent an alkyl group, an alkoxy group, an alkylthio group, a monoalkylamino group or a dialkylamino group each of which may be substituted by a halogen atom; k represents 0 or 1; l represents 2 or 3; m represents an integer of 1 to 6; and r represents 1 or 2; wherein, when k is 0, 1 is 3, m is 1 and all of three bonds of A are bonded to Z.

公开(公告)号：US20210317083A1

公开(公告)日：2021-10-14

申请号：US17268958

申请日：2019-08-19

申请人： KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

发明人： Ki Duk PARK ,  Ae Nim PAE ,  Sang Min LIM ,  Jong Hyun PARK ,  Ji Won CHOI ,  Siwon KIM ,  Hyeon Jeong KIM ,  Seul Ki YEON

IPC分类号： C07D213/52 ,  C07F9/40

摘要： The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

公开(公告)号：US11130772B2

公开(公告)日：2021-09-28

申请号：US15113139

申请日：2015-01-21

申请人： MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN ,  BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Wolf-Hagen Schunck ,  Dominik Mueller ,  Robert Fischer ,  Gerd Wallukat ,  Anne Konkel ,  John Russell Falck

IPC分类号： C07F9/38 ,  C07C309/21 ,  C07C311/51 ,  C07C323/41 ,  C07D277/82 ,  C07D291/04 ,  C07F9/40

摘要： The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

公开(公告)号：US11098072B2

公开(公告)日：2021-08-24

申请号：US16627004

申请日：2018-06-27

申请人： The George Washington University ,  Washington University in St. Louis ,  George Mason University ,  Saint Louis University

发明人： Cynthia Dowd ,  Xu Wang ,  Robert Carl Brothers ,  Audrey Ragan Odom John ,  Rachel Edwards ,  Marvin Meyers ,  Stacy Arnett ,  Robin Couch ,  Kenneth Heidel

IPC分类号： C07F9/38 ,  A61P33/06 ,  A61P31/06 ,  C07F9/40

摘要： The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are α,β-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.